Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs DXCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–2 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: SYK 3 – 3 DXCM Matrix Metrics: SYK 2 – 7 DXCM

As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin).

  • Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs DXCM
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$81.58
-2.11% 1D
Market Cap $30.4B
TTM Revenue $5.10B
Forward P/E 26.6x
Beta / 30D Vol 0.61β · 49% Vol
Unified Composite Score
53.8 / 100 HOLD
Tech 74.0 Fund 67.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -3.9%) with fading momentum, RSI 49
RSI-14: 49.4 · SMA20: $81.44 · SMA50: $84.19

6-Pillar Scorecard Institutional Category Breakdown (SYK 3 – 3 DXCM)

Columns: Metric · SYK · DXCM
1. Valuation Multiples SYK
Forward P/E 19.0x 26.6x
Trailing P/E 33.3x 32.0x
PEG Ratio 1.54x 1.27x
EV / Revenue 5.0x 6.0x
2. Growth & Scale DXCM
Revenue Growth (YoY) +7.6% +11.2%
Earnings Growth (YoY) -11.7% +2.6%
TTM Revenue (USD) $26.3B $5.10B
Market Cap $118.9B $30.4B
3. Profitability & Quality DXCM
Gross Margin 65.7% 63.4%
Operating Margin 24.0% 24.0%
Net Profit Margin 13.8% 19.4%
Return on Equity (ROE) 16.0% 37.7%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $4.57B $1.73B
Cash Flow Margin 17.4% 33.9%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $432M Net Debt (0.55x D/E)
Dividend Yield 1.10% None (0.00%)
5. Options & Positioning SYK
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 28.1% (5th %ile) 36.9% (9th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.64x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 39.4% of Rev ($2.01B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (2) vs DXCM (7)
Institutional Metric SYK DXCM Criterion Row Edge
Market Capitalization
Scale
$118.9B $30.4B Larger Scale SYK
Trailing P/E Ratio
Valuation
33.3x 32.0x Lower Multiple DXCM
Forward P/E Ratio
Valuation
19.0x 26.6x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+7.6% +11.2% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 24.0% Higher Margin Tie
Net Profit Margin
Profitability
13.8% 19.4% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
16.0% 37.7% Higher ROE DXCM
52-Week Range Position
Momentum
36% ($267–$389) 69% ($57–$93) Stronger Trend DXCM
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.61β · 49% Vol Lower Realized Risk DXCM
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 53.8 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $5.10B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 63.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 1.27x PEG · 6.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $1.73B ($432M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYK +10.66 pp
SYK: +5.47% · DXCM: -5.19%
3M Horizon SYK +2.75 pp
SYK: -6.21% · DXCM: -8.96%
6M Horizon DXCM +26.11 pp
SYK: -0.78% · DXCM: +25.33%
1Y Horizon DXCM +53.37 pp
SYK: -16.77% · DXCM: +36.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue DXCM Revenue SYK Op. Margin DXCM Op. Margin Margin Leader
FY2018 $13.6B $1.03B 18.7% -18.1% SYK
FY2019 $14.9B $1.48B 18.2% 9.6% SYK
FY2020 $14.3B $1.93B 15.5% 15.5% Tie
FY2021 $17.1B $2.45B 15.1% 10.9% SYK
FY2022 $18.4B $2.91B 15.4% 13.4% SYK
FY2023 $20.5B $3.62B 19.0% 16.5% SYK
FY2024 $22.6B $4.03B 16.3% 14.9% SYK
FY2025 $25.1B $4.66B 19.5% 19.6% DXCM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXCM CONSOLIDATION
69d in phase · OBV NEUTRAL
Current IV 36.9%
IV Percentile 9th %ile
Put/Call OI Skew 0.64x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $30.4B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs DXCM Key Questions & Quantitative Answers

As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: SYK trades in a Neutral technical trend (SURGE options phase, RSI 51.5); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while DXCM shifted +352.4%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.

SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas DXCM trades at 26.6x Forward P/E, 32.0x Trailing P/E, 1.27x PEG, and 6.0x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus DXCM (37.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, DXCM carries 36.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.